LandmarkRCT

SID-GBS

Primary publication linked by DOI, 2021 · Multicenter double-blind placebo-controlled RCT

Population: 93 treated patients ≥12 years with predicted poor prognosis after standard IVIG
Intervention: Second IVIG course
Comparator: Placebo
Primary outcome: GBS disability at four weeks
Result: Adjusted common OR 1.4 (95% CI 0.6–3.3), P=.45; serious adverse events 35% versus 16%.

What the trial found

Adjusted common OR 1.4 (95% CI 0.6–3.3), P=.45; serious adverse events 35% versus 16%.

Clinical interpretation

Do not repeat IVIG solely for poor predicted prognosis; this does not settle treatment-related fluctuation.

Moderate certainty

Clinical Context & Relevant Topics (1)

Disease Reference

Guillain–Barré Syndrome (GBS)

Dedicated ICU GBS care: respiratory surveillance, autonomic instability, IVIG/plasma exchange, airway strategy, pain/DVT prevention, and complications.

View Topic Context →